ISRG SEC Filings

Intuitive Surgical Inc. (ISRG) reported robust growth in its 2025 fiscal year, with total revenue increasing by 21% to $10.1 billion. This growth was driven by a significant increase in da Vinci procedures (up 18%) and Ion procedures (up 51%), indicating strong adoption of the company's minimally invasive robotic surgical systems and diagnostic platforms. The company saw substantial growth in both systems revenue (+26%) and instruments and accessories revenue (+19%), reflecting increased unit placements for its da Vinci surgical systems, particularly the new da Vinci 5 model. The installed base of da Vinci systems grew by 12% to over 11,100 units, while the Ion system installed base increased by 24%. Despite strong revenue growth, the gross profit margin for products decreased slightly to 66.0% from 67.5% in the prior year, attributed to factors including new tariffs, higher costs associated with the da Vinci 5, and increased depreciation, though partially offset by lower excess inventory charges. Looking ahead, ISRG continues to invest heavily in research and development to drive innovation, while also navigating macroeconomic challenges such as tariffs, inflation, and supply chain constraints. The company's financial position remains strong, with over $9 billion in cash, cash equivalents, and investments, providing ample resources to fund future growth and strategic initiatives.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on January 22, 2026, primarily to furnish a press release detailing its financial results for the quarter ended December 31, 2025. While the full financial details are within the press release (Exhibit 99.1), the filing itself does not contain new operational or financial data beyond referencing this external announcement. Investors should refer to the press release for specific performance metrics, revenue figures, and any forward-looking statements or guidance provided by the company. This filing serves as a notification to the market that the company's fourth-quarter and full-year 2025 financial results are now publicly available. The 8-K format indicates that this information is being disclosed in accordance with regulatory requirements, but the company has stipulated that this information is furnished and not deemed "filed" for purposes of certain securities laws, limiting its incorporation by reference into other SEC filings.

Intuitive Surgical, Inc. (ISRG) has filed a Current Report on Form 8-K on January 14, 2026, to announce preliminary, unaudited financial results for the fourth quarter and full year of 2025. The report indicates that a press release (Exhibit 99.1) has been issued detailing these results, along with additional preliminary revenue and procedure information (Exhibit 99.2) that has also been made available on the company's Investor Relations website. Investors should note that this information is preliminary and furnished, not filed, meaning it is not subject to the liabilities of Section 18 of the Exchange Act and is not incorporated by reference into other filings.

Intuitive Surgical, Inc. (ISRG) has announced a leadership transition effective January 1, 2026. Brian E. Miller, Ph.D., will be stepping down as Chief Digital Officer. While this role change might initially suggest a shift in focus, Dr. Miller will remain with the company in a newly created position: Head of Digital and AI Strategy. This move indicates a continued commitment to advancing the company's digital and artificial intelligence initiatives, albeit with a restructured reporting line.

Intuitive Surgical Inc. (ISRG) reported strong revenue growth for the third quarter and first nine months of fiscal year 2025, with total revenue increasing by 23% and 21%, respectively, year-over-year. This growth was driven by robust performance across all segments, including a significant increase in instruments and accessories revenue (20% and 19%) and systems revenue (33% and 29%). The company also saw substantial growth in da Vinci procedures (19% and 18% for the quarter and nine months, respectively) and Ion procedures (52% and 54%). The company continues to expand its installed base, with da Vinci systems increasing by 13% year-over-year and Ion systems by 30%. Profitability also saw a significant boost, with operating income up 32% year-over-year for the quarter. Despite the strong top-line and bottom-line performance, investors should note a slight decline in gross profit margin as a percentage of revenue for both product and service segments, primarily attributed to the impact of tariffs and increased costs related to the phased launch of the new da Vinci 5 system. The company also repurchased a significant amount of its common stock, totaling $1.92 billion in the third quarter. Management remains optimistic about future growth, driven by expanding procedure adoption, new product introductions, and international market penetration, though they acknowledge ongoing macroeconomic and geopolitical risks.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on October 21, 2025, to announce its financial results for the quarter ended September 30, 2025. The primary purpose of this filing is to furnish a press release containing these results, which was issued on the same date. Investors should refer to the attached press release (Exhibit 99.1) for detailed financial performance and operational updates for the period. While the 8-K itself does not contain the specific financial figures, it serves as the official notification that these results are now public. The company has provided standard disclosures regarding the informational status of this filing, clarifying that it is furnished and not deemed "filed" under Section 18 of the Exchange Act. This means the information is for disclosure purposes and does not carry the same legal implications as a formally filed document in that regard.

Intuitive Surgical, Inc. (ISRG) reported strong financial performance for the quarter and first half of 2025, demonstrating robust revenue growth across its key segments. Total revenue increased by 21% year-over-year to $2.44 billion for the three months ended June 30, 2025. This growth was driven by a significant uptick in da Vinci procedure volume (up 17%), higher systems revenue (up 28%), and increased instruments and accessories revenue (up 18%), signaling continued adoption and utilization of their robotic-assisted surgical systems. The company also saw a substantial increase in Ion endoluminal system procedures, up 52% year-over-year, highlighting the growing adoption of their diagnostic platform. Despite increased costs related to the launch of the da Vinci 5 system, tariffs, and expanded manufacturing capacity, gross profit margin remained solid at 66.3%. Operating income saw a healthy increase of 31% to $743 million. The company ended the period with a strong cash position of $3.4 billion and significant investments, underscoring its financial health and capacity for future growth and strategic initiatives.

Intuitive Surgical, Inc. (ISRG) filed an 8-K on July 22, 2025, to announce its financial results for the quarter ended June 30, 2025. The primary purpose of this filing is to furnish a press release that details the company's performance and financial condition for the period. Investors should refer to the press release (Exhibit 99.1) for specific details regarding revenue, profitability, procedure volumes, and any forward-looking statements or guidance provided by the company. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification mechanism for the release of this information. The furnished press release is the key document for understanding ISRG's operational and financial results for the second quarter of 2025, offering insights into the continued adoption and utilization of their robotic surgical systems. Investors are encouraged to review the full press release for a comprehensive understanding.

Intuitive Surgical, Inc. (ISRG) announced significant leadership changes effective July 1, 2025. David J. Rosa, currently President, will be appointed Chief Executive Officer, succeeding Dr. Gary S. Guthart. Dr. Guthart will transition to the role of Executive Chair of the Board, retaining his director position. Craig H. Barratt, Ph.D., current Board Chair, will assume the role of lead independent director. These changes reflect a planned succession and aim to leverage Mr. Rosa's extensive experience within the company for future growth. In conjunction with these transitions, compensation adjustments have been made. Mr. Rosa's base salary will increase, and his bonus target will be enhanced, alongside significant equity awards in the form of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). Dr. Guthart's compensation will be adjusted to reflect his new role as Executive Chair and senior advisor, with a reduced base salary and no bonus eligibility going forward, though he will receive a pro-rated bonus for fiscal year 2025. These moves are designed to ensure a smooth leadership transition and align executive incentives with the company's strategic objectives.

Intuitive Surgical Inc. (ISRG) filed an 8-K report detailing outcomes from their Annual Meeting of Stockholders held on May 1, 2025, and an increase in their stock repurchase program. Key among the meeting's outcomes was the stockholder approval of the amendment and restatement of the Amended and Restated 2010 Incentive Award Plan. This amendment increases the number of shares reserved for issuance by 5 million, extends the plan's term to January 30, 2035, and clarifies treatment of awards in change-in-control scenarios. Additionally, all eleven director nominees were elected to the Board, and advisory approval was given for executive compensation. Further enhancing shareholder value initiatives, the Board of Directors approved an increase to the common stock repurchase program by $4.0 billion, encompassing previously authorized but unused amounts. This signifies management's confidence in the company's financial health and commitment to returning capital to shareholders. While most proposals passed with strong support, two shareholder proposals concerning executive compensation and golden parachutes were rejected by a significant margin.

Intuitive Surgical Inc. (ISRG) reported strong financial results for the first quarter of 2025, demonstrating robust top-line growth and continued expansion in its core robotic surgery business. Total revenue increased by a significant 19% year-over-year to $2.25 billion, driven by strong performance across all revenue segments, particularly in instruments and accessories, systems, and services. The company saw a substantial increase in da Vinci procedure volume, up 17%, alongside a notable 58% surge in Ion endoluminal procedures, indicating growing adoption of its minimally invasive solutions. Key financial metrics highlight the company's operational efficiency and continued investment in innovation. Gross profit margin remained healthy at 64.7%, with operating income growing 23%. The company also reported a healthy cash position, ending the quarter with $9.10 billion in cash, cash equivalents, and investments, providing ample liquidity for future growth initiatives, ongoing R&D, and potential strategic acquisitions. The increase in systems revenue and strong da Vinci 5 system placements signal positive market reception for newer generation products.

Intuitive Surgical, Inc. (ISRG) has filed a Form 8-K on April 22, 2025, to report on its financial results for the quarter ended March 31, 2025. The primary purpose of this filing is to furnish a press release containing these results, which was issued on the same day. Investors should refer to this press release (Exhibit 99.1) for detailed information on the company's performance during the first quarter of fiscal year 2025. While the 8-K itself is brief and primarily an informational filing vehicle for the press release, the attached press release is expected to contain key financial metrics such as revenue, earnings per share, and potentially procedural volumes. Investors are advised to analyze these results carefully to understand the company's growth trajectory, operational efficiency, and overall financial health in the context of the current market and competitive landscape. The filing also clarifies that the information furnished is not considered 'filed' for Section 18 purposes, a standard disclaimer for such reports.

Intuitive Surgical, Inc. (ISRG) filed its annual report for the period ending December 30, 2024, highlighting robust revenue growth and continued expansion of its da Vinci surgical system installed base. Total revenue increased by 17% to $8.4 billion, driven by a strong performance in instruments and accessories revenue (up 19%) and systems revenue (up 17%). The company also saw significant growth in its Ion endoluminal system procedures (up 78%). The da Vinci system installed base grew 15% to 9,902 units globally, with 1,526 new systems placed during the year. This growth reflects increasing adoption across key surgical specialties, particularly in general surgery, gynecology, and urology, both domestically and internationally. The company is also investing in new product development, including the next-generation da Vinci 5 system and the E-200 generator, and expanding its manufacturing capabilities. Despite strong operational performance, the company faces ongoing risks including intense competition, potential disruptions to its supply chain, regulatory complexities, and macroeconomic headwinds such as inflation and interest rate volatility. The company's significant international operations also expose it to currency fluctuations and varied regulatory environments. Management remains focused on innovation, expanding access to minimally invasive care, and optimizing its business strategy to navigate these challenges and capitalize on future growth opportunities.

Intuitive Surgical, Inc. (ISRG) filed an 8-K on January 23, 2025, announcing its financial results for the quarter ended December 31, 2024, in an accompanying press release (Exhibit 99.1). While specific financial figures from the earnings release are not detailed in the 8-K itself, this filing signals the release of their latest quarterly performance data to the public. Investors should refer to the furnished press release for a comprehensive understanding of ISRG's financial condition and operational results for the period. In addition to financial results, the 8-K also disclosed a significant strategic acquisition. On January 21, 2025, Intuitive announced a definitive agreement to acquire the da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino from current distributors ab medica, Abex, and Excelencia Robotica. This acquisition involves an upfront cash payment of approximately €290 million, with potential for an additional €31 million in milestone payments. The transaction is expected to close in the first half of 2026, subject to customary conditions, and represents a move to strengthen ISRG's direct control over key European distribution channels.

Intuitive Surgical, Inc. (ISRG) has filed a Form 8-K report on January 15, 2025, announcing unaudited preliminary financial results for the fourth quarter and full year of 2024. This filing serves to provide investors with early insights into the company's performance ahead of more detailed reporting. The report primarily consists of a press release and supplementary tables containing preliminary revenue and procedure data. While these results are preliminary and unaudited, they offer investors a glimpse into the company's operational and financial trajectory for the period. The company has furnished these documents, making them available to the public through the filing and its Investor Relations website, underscoring a commitment to transparency.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report detailing significant executive promotions effective January 1, 2025. Jamie E. Samath has been elevated to Executive Vice President, Chief Financial Officer, and Head of Business Technology. Concurrently, Henry L. Charlton has been promoted to Executive Vice President, Chief Commercial and Marketing Officer. These appointments signify a recognition of their contributions and likely reflect a strategic alignment within the company's leadership structure as it continues to navigate the evolving landscape of robotic-assisted surgery.

Intuitive Surgical Inc. (ISRG) reported strong third-quarter results for the period ending September 29, 2024, demonstrating robust top-line growth and improving profitability. Total revenue surged 17% year-over-year to $2.04 billion, fueled by significant increases in both instruments and accessories revenue (+18%) and systems revenue (+17%). This growth was primarily driven by a 17% increase in total da Vinci procedures and the successful launch and placement of 110 new da Vinci 5 systems during the quarter. The company also reported a substantial increase in operating income, up 24% to $577 million, reflecting improved gross margins to 67.4% and effective management of operating expenses. This strong financial performance, coupled with a growing installed base of da Vinci and Ion systems, positions Intuitive Surgical favorably. The company maintains a healthy balance sheet with $8.31 billion in cash, cash equivalents, and investments, providing ample resources for continued investment in innovation and global expansion.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on October 17, 2024, to announce its financial results for the quarter ended September 30, 2024. The key information is contained within the furnished press release (Exhibit 99.1), which provides the company's performance details for the period. Investors should refer to this press release for specifics on revenue, profitability, and any other significant operational metrics. While the 8-K itself does not contain the financial figures, it formally incorporates the press release which serves as the primary source of updated financial information. It's important to note that this information is furnished and not deemed 'filed' for certain regulatory purposes, a standard disclosure for such filings.

Intuitive Surgical, Inc. (ISRG) has announced a significant update to its Board of Directors. Effective July 24, 2024, David J. Rosa has been appointed as a new member to the Board. This appointment also coincides with an increase in the authorized number of Board members to 12, indicating a strategic expansion of its governance structure. Mr. Rosa's appointment does not involve any disclosable material interests, ensuring a clean transition. The company further disseminated this news through a press release on July 25, 2024. This move suggests a potential focus on strengthening strategic oversight and leadership as the company continues to innovate and grow within the robotic-assisted surgical market.

Intuitive Surgical Inc. (ISRG) reported strong revenue growth in the second quarter of 2024, with total revenue increasing by 14% year-over-year to $2.01 billion. This growth was driven by robust performance in instruments and accessories, systems, and services, fueled by a 17% increase in da Vinci procedures and an impressive 82% surge in Ion procedures. The company also saw a healthy 14% increase in da Vinci system placements and a significant 56% expansion in its Ion system installed base. Profitability metrics improved, with gross profit margin increasing to 68.3% and operating income growing by 22%. The company maintains a strong balance sheet with $7.68 billion in cash, cash equivalents, and investments, indicating solid financial health and capacity for continued investment in growth and innovation.

Intuitive Surgical, Inc. (ISRG) filed an 8-K on July 18, 2024, to announce its financial results for the second quarter ended June 30, 2024. The report primarily consists of a press release detailing these results, which is furnished as Exhibit 99.1. Investors should note that this information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal liabilities and is not automatically incorporated into other SEC filings. While the 8-K itself is a procedural filing, the attached press release contains the crucial financial and operational updates. Investors will need to refer to Exhibit 99.1 for specific details on revenue, earnings, procedure volumes, and any forward-looking guidance provided by the company. This filing serves as the official notification of the company's performance during the recently concluded quarter.

Intuitive Surgical, Inc. filed an 8-K report on April 29, 2024, detailing key events from its Annual Stockholders' Meeting held on April 24, 2024. The primary focus for investors is the outcome of the shareholder votes, which saw all incumbent directors re-elected and approval of executive compensation on an advisory basis. Significant governance changes include the appointment of Lewis Chew as the new Chair of the Audit Committee and Jami Dover Nachtsheim as the new Chair of the Governance and Nominating Committee. Investors will also note the approval of the amendment and restatement of both the 2010 Incentive Award Plan and the 2000 Employee Stock Purchase Plan, indicating continued support for the company's equity incentive structures. The ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024 reinforces auditor confidence. Importantly, a shareholder proposal requesting a racial and gender pay gap report was narrowly rejected, highlighting ongoing discussions around corporate social responsibility metrics.

Intuitive Surgical Inc. (ISRG) reported strong financial results for the first quarter of 2024, demonstrating robust growth across key operational and financial metrics. Total revenue increased by 11% year-over-year to $1.89 billion, driven by a significant 18% rise in instruments and accessories revenue and an 11% increase in service revenue. The company also saw substantial procedure growth, with da Vinci procedures up 16% and Ion procedures nearly doubling at a 90% increase. This growth is supported by an expanding installed base of da Vinci systems, up 14% year-over-year, and a 61% increase in Ion systems. Despite a slight 2% decrease in systems revenue, attributed to a higher proportion of systems placed under operating leases, the company's operational performance remains strong. Profitability also improved, with operating income increasing by 21% and gross profit margin holding steady at 65.9%. The company ended the quarter with a healthy cash position of $7.32 billion.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on April 17, 2024, to announce its financial results for the quarter ended March 31, 2024. The key details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profit, and operational updates related to their robotic-assisted surgical systems.

Intuitive Surgical, Inc. (ISRG) has announced a significant development with the U.S. Food and Drug Administration (FDA) clearance of its fifth-generation robotic system, the da Vinci 5. This clearance represents a key milestone for the company, signaling the introduction of its latest technological advancements in robotic-assisted surgery to the market. Investors should pay close attention to the upcoming teleconference scheduled for March 18, 2024. This event will provide detailed insights into the da Vinci 5's new features, its expected benefits for surgical procedures, and the company's strategic launch plans. The availability of a webcast and replay ensures accessibility for all interested parties, offering an opportunity to gain a deeper understanding of how this new system might impact ISRG's future growth and competitive positioning.

Intuitive Surgical Inc. (ISRG) demonstrated robust financial performance in its 2023 fiscal year, reporting a 14% increase in total revenue to $7.1 billion. This growth was primarily driven by a strong 22% increase in instruments and accessories revenue, reflecting higher da Vinci procedure volumes, which rose 22% to approximately 2.3 million procedures. The company also saw a significant 129% surge in Ion procedures. Despite flat systems revenue, the installed base of da Vinci systems grew by 14% to 8,606 units, indicating continued market penetration and utilization. The company's strategic focus on expanding its minimally invasive care ecosystem, including its Ion endoluminal system, and its commitment to innovation and customer training are key drivers of its success. While facing macroeconomic headwinds such as inflation and higher interest rates, which have impacted customer capital spending, ISRG has managed its operations effectively, maintaining a solid cash position and continuing to invest in research and development to drive future growth. The company's extensive risk factor disclosures highlight the competitive landscape, regulatory environment, and supply chain challenges as areas of ongoing attention.

Intuitive Surgical, Inc. (ISRG) has filed a Form 8-K on January 23, 2024, to report its financial results for the fourth quarter and full year ended December 31, 2023. The filing primarily contains a press release detailing these results, which is furnished as Exhibit 99.1. This report signals the company's performance in the most recent fiscal period, offering investors key insights into revenue, profitability, and operational achievements. Investors should refer to the furnished press release for the specific financial figures and management commentary. While the 8-K itself does not contain the detailed financial statements, it serves as the official notification of the release of this information. The press release is expected to cover important metrics such as system placements, procedure volumes, and the performance of their various product lines, which are crucial for understanding ISRG's growth trajectory and market position in the robotic-assisted surgery sector. The furnished information is not considered "filed" for the purposes of Section 18 of the Exchange Act.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on January 9, 2024, to announce preliminary, unaudited financial results for the fourth quarter and full year of 2023. The filing includes a press release and supplementary tables detailing revenue and procedure information, which are furnished but not deemed "filed" under SEC regulations. Investors should refer to the furnished exhibits for specific financial figures and operational metrics, as these provide an early look at the company's performance leading into its official earnings release.

Intuitive Surgical, Inc. (ISRG) announced a key board appointment and related compensation details in its latest 8-K filing. Sreelakshmi Kolli has been appointed to the Board of Directors, effective October 27, 2023. This appointment also led to an increase in the authorized board size to 12 members. Ms. Kolli's compensation includes an annual cash retainer, stock options, and restricted stock units, with grant values and vesting schedules detailed in the filing.

Intuitive Surgical Inc. (ISRG) reported robust financial performance for the nine months ended September 30, 2023, with total revenue reaching $5.20 billion, a 14% increase year-over-year. This growth was driven by strong performance in instruments and accessories (up 22%) and service revenue (up 13%), indicating increased utilization of their da Vinci surgical systems. While system revenue saw a slight decrease of 2%, this was offset by a higher proportion of placements under operating leases, which generate recurring revenue over time. The company demonstrated solid profitability with an operating income of $1.32 billion for the nine-month period, up 9% year-over-year. Net income attributable to Intuitive Surgical, Inc. increased by 19% to $1.19 billion. The company maintained a strong liquidity position, with cash, cash equivalents, and investments totaling $7.52 billion as of September 30, 2023. ISRG also continued its commitment to shareholder returns, repurchasing $350 million of its common stock during the nine-month period, while maintaining a significant remaining authorization for future repurchases.

Intuitive Surgical, Inc. (ISRG) announced its financial results for the quarter ended September 30, 2023, via a press release filed on October 19, 2023. While the 8-K filing itself does not contain the detailed financial figures, it serves as notification that the company has issued its earnings release. Investors should refer to the furnished press release (Exhibit 99.1) for specific operational and financial performance data, including key metrics like robot system placements, procedure volumes, and revenue generated during the third quarter of 2023. This filing is primarily procedural, indicating the official release of the company's quarterly performance. The press release will contain the crucial information regarding the company's top-line growth, profitability, and any forward-looking statements or guidance provided by management. Investors are advised to carefully review the full press release for a comprehensive understanding of the company's current financial health and future outlook.

Intuitive Surgical, Inc. (ISRG) reported robust performance in its second quarter and first half of 2023, demonstrating continued growth in revenue and procedures. Total revenue increased by 15% year-over-year for the quarter, reaching $1.76 billion, driven by strong performance in instruments and accessories, services, and systems. This growth was fueled by a significant 22% increase in da Vinci procedures globally, alongside a substantial 145% rise in Ion procedures. The company continues to expand its installed base, with da Vinci surgical systems increasing by 13% year-over-year to 8,042, and the Ion system seeing over a 100% increase in its installed base. Profitability remains strong, with operating income up 16% year-over-year for the quarter. Despite ongoing macroeconomic challenges such as inflation and supply chain pressures, ISRG has managed to mitigate these impacts, reporting that supply chain disruptions have not materially affected results to date. The company maintains a strong liquidity position with $7.13 billion in cash, cash equivalents, and investments as of June 30, 2023.

Intuitive Surgical, Inc. (ISRG) announced its financial results for the second quarter ended June 30, 2023, via a press release filed on July 20, 2023. This filing provides investors with the company's latest operational and financial performance update. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished press release (Exhibit 99.1) for these critical data points, including revenue, earnings, and operational metrics. Investors should refer to this press release for a comprehensive understanding of the company's performance during the reported quarter.

Intuitive Surgical, Inc. (ISRG) has announced a key executive leadership change via an 8-K filing on May 16, 2023. David J. Rosa has been promoted to President, effective May 16, 2023. He will report to CEO Gary S. Guthart, who will relinquish the President title but remain CEO and a board member. This promotion signifies a strategic move to leverage Mr. Rosa's extensive experience in commercial, scientific, and strategic roles within the company since 1996. In conjunction with his new role, Mr. Rosa will receive a salary increase to $700,000 and an enhanced bonus target of 120% of his base salary for fiscal year 2023. Additionally, he has been granted significant equity awards, including stock options, RSUs, and PSUs, valued at $1.5 million, $1.5 million, and $2 million, respectively. These awards are designed to align his compensation with long-term company performance and shareholder value. The appointment suggests a continued focus on growth and operational leadership within Intuitive Surgical.

Intuitive Surgical, Inc. (ISRG) filed an 8-K report detailing the outcomes of its Annual Meeting of Stockholders held on April 26, 2023. The report confirms that all key proposals presented to shareholders received strong support, indicating alignment between management and its investors on critical governance matters. Notably, all eleven director nominees were elected, and the company's executive compensation plan was approved on an advisory basis, with shareholders preferring an annual frequency for such votes going forward. The ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023 also passed overwhelmingly, reinforcing confidence in the company's financial oversight. However, a shareholder proposal concerning pay equity disclosure was not approved. Overall, the filing suggests a stable and supportive shareholder base for the company's current leadership and financial reporting practices.

Intuitive Surgical, Inc. (ISRG) reported its first-quarter 2023 financial results, showcasing robust growth driven by increased da Vinci procedure volumes and strong performance in instruments and accessories. Total revenue grew 14% year-over-year to $1.7 billion, with instruments and accessories revenue up 22% to $986 million, largely fueled by a 26% increase in da Vinci procedures globally. While systems revenue remained flat year-over-year at $427 million, this was driven by higher leasing revenue, offsetting a greater proportion of systems placed under operating leases. The company maintained a strong installed base, with da Vinci systems growing 12% to 7,779 and Ion systems growing 131% to 376. Despite revenue growth, operating income saw a slight decrease of 5% to $388 million, primarily due to increased operating expenses, including higher R&D and SG&A costs related to investments in future growth and share-based compensation. The company's gross profit margin also compressed slightly to 65.6% from 67.9% in the prior year, impacted by higher component and labor costs. Intuitive Surgical ended the quarter with a healthy cash position of $6.58 billion, but significant share repurchases and capital expenditures are noted. Key risks and considerations include ongoing macroeconomic challenges such as inflation and rising interest rates, which may impact hospital capital spending, as well as supply chain constraints that continue to pose a challenge. The company is actively managing these risks while investing in innovation and expanding its global reach.

Intuitive Surgical, Inc. (ISRG) filed an 8-K on April 18, 2023, to announce its financial results for the first quarter ended March 31, 2023. The company furnished a press release (Exhibit 99.1) detailing these results. Investors should note that the information provided in this filing is furnished and not deemed "filed" for the purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal liabilities and is not automatically incorporated into future filings unless explicitly stated. While the full details of the financial results are within the furnished press release (Exhibit 99.1), the core purpose of this 8-K filing is to make these Q1 2023 earnings publicly accessible. Investors seeking specific financial metrics such as revenue, net income, earnings per share, and operational highlights (e.g., system placements, procedure volumes) will need to refer to the press release itself.

Intuitive Surgical, Inc. (ISRG) filed its 2022 10-K report, detailing its continued growth in a dynamic global healthcare landscape. The company saw an 18% increase in da Vinci procedures, reaching approximately 1.875 million, alongside a substantial 218% rise in Ion system procedures to 23,500. This procedural growth drove a 13% increase in instruments and accessories revenue, highlighting the recurring revenue model's strength. However, systems revenue saw a slight 1% decrease, attributed to macroeconomic pressures, particularly in the U.S., which impacted hospital capital spending, and a 6% decline in da Vinci system placements. Despite these system placement challenges, the overall installed base of da Vinci systems grew by 12% to 7,544 units, indicating ongoing market penetration and adoption. The company's financial performance in 2022 showed total revenue growth of 9% to $6.2 billion, though operating income decreased by 13% to $1.58 billion, impacted by increased investments in R&D and SG&A expenses, including higher headcount and infrastructure costs. The gross profit margin also saw a slight decrease to 67.4% from 69.3% in the prior year, influenced by rising freight and material costs and unfavorable foreign currency impacts. Looking ahead, Intuitive Surgical faces ongoing risks related to macroeconomic conditions, supply chain constraints, and potential regulatory changes. The company is actively managing these challenges by focusing on innovation, expanding its product portfolio, and investing in its global infrastructure to support long-term growth and its mission of advancing minimally invasive care.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on January 24, 2023, primarily to furnish a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022. While the 8-K itself does not contain the detailed financial data, it directs investors to the furnished press release (Exhibit 99.1) for this crucial information. Investors should consult this press release for specific figures related to revenue, profit, system placements, and procedure growth, which are key performance indicators for ISRG.

Intuitive Surgical, Inc. (ISRG) has filed a Form 8-K to report preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2022. The filing includes a press release and tables detailing revenue and procedure information, which are furnished as exhibits and available on the company's investor relations website. While these results are preliminary and not yet finalized, they provide early insights into the company's performance for the period.

Intuitive Surgical, Inc. (ISRG) announced on October 24, 2022, that it has entered into an accelerated share repurchase (ASR) agreement with Citibank, N.A., to repurchase an aggregate of $1 billion of its common stock. Under the terms of the agreement, ISRG will make an initial payment of $1 billion and will receive an initial delivery of approximately 3.6 million shares. The final number of shares repurchased will be determined based on the volume-weighted average price during the repurchase period, with final settlement expected in late December 2022. This significant share repurchase program signals management's confidence in the company's valuation and its commitment to returning capital to shareholders. Investors should view this ASR as a positive indicator, suggesting that the company believes its stock is undervalued and that it anticipates strong future performance. The repurchase is expected to reduce the number of outstanding shares, potentially boosting earnings per share (EPS) and overall shareholder value.

Intuitive Surgical Inc. (ISRG) reported its third-quarter and nine-month results for the period ending September 29, 2022. Total revenue for the third quarter increased by 11% year-over-year to $1.56 billion, driven by a 20% increase in da Vinci procedures and a 15% rise in instruments and accessories revenue. However, system placements saw a slight decrease of 9% year-over-year to 305 units, impacted by macroeconomic challenges and fewer system trade-ins. For the nine-month period, total revenue grew 10% to $4.57 billion, with a 18% increase in procedures and a 14% rise in instruments and accessories revenue, while system placements decreased by 7% to 895 units. The company highlighted strong procedure growth both in the U.S. and internationally, particularly in general surgery and urology. Despite the revenue growth, operating income for the third quarter decreased by 10% to $399 million due to increased operating expenses, including higher selling, general, and administrative (SG&A) and research and development (R&D) costs, as well as a decline in gross profit margin from 69.2% to 67.6%. The company's balance sheet remains strong with $7.39 billion in cash, cash equivalents, and investments as of September 30, 2022, though this represents a decrease from the prior year-end due to significant share repurchases and capital expenditures.

Intuitive Surgical, Inc. (ISRG) has filed an 8-K report on October 18, 2022, primarily to furnish a press release detailing its financial results for the third quarter ended September 30, 2022. While the specific financial figures are within the furnished press release (Exhibit 99.1), this 8-K filing itself acts as notification of these results becoming public. Investors should refer to the press release for comprehensive details on revenue, profitability, procedure volumes, and any forward-looking guidance provided by the company. The significance of this filing lies in its role as an official channel for disseminating quarterly financial performance. Investors and analysts will be scrutinizing the press release for key metrics that reflect the company's growth trajectory, operational efficiency, and market position in robotic-assisted surgery. Any deviations from expectations, positive or negative, regarding procedure growth, instrument and accessory sales, or system placements will be critical for assessing the company's ongoing performance and future outlook.

Intuitive Surgical, Inc. (ISRG) announced on August 1, 2022, that it has entered into an Accelerated Share Repurchase (ASR) agreement with Goldman Sachs & Co. LLC to buy back $1 billion of its common stock. Under this agreement, the company will pay $1 billion upfront and will receive an initial delivery of approximately 3.5 million shares. The final number of shares repurchased will be determined based on the volume-weighted average price during the repurchase period, with potential adjustments at settlement. This significant capital return to shareholders signals management's confidence in the company's financial health and its stock valuation. Investors should note that the ASR is expected to conclude in approximately three months, though it may be accelerated. The terms include mechanisms for determining the final share count and potential adjustments, highlighting the complexity of such transactions. While the company expects to repurchase a substantial amount of stock, the exact number of shares will be subject to market conditions and the terms of the ASR.

Intuitive Surgical Inc. (ISRG) reported its financial results for the quarter and six months ended June 30, 2022. Total revenue for the quarter increased by 4% year-over-year to $1.52 billion, driven by a 12% increase in instruments and accessories revenue, largely due to a 14% rise in da Vinci procedures. However, systems revenue saw a 15% decline, impacted by fewer system placements and supply chain challenges. The company's installed base of da Vinci Surgical Systems grew by 13% year-over-year to 7,135 systems. For the six-month period, total revenue grew by 9% to $3.0 billion, with instruments and accessories revenue up 14% and service revenue up 12%, while systems revenue remained flat. The company continues to invest significantly in research and development, with R&D expenses increasing by 30% year-over-year for the six-month period, indicating a focus on future innovation. Despite revenue growth, operating income decreased by 22% for the quarter due to increased operating expenses, including higher selling, general, and administrative costs and research and development expenses.

Intuitive Surgical, Inc. (ISRG) announced its financial results for the second quarter ended June 30, 2022, via a press release filed on July 21, 2022. This filing primarily serves to furnish the press release detailing these results, making it accessible to investors. While the 8-K itself doesn't contain the specific financial figures, it directs stakeholders to the comprehensive press release for this crucial information. Investors should refer to the furnished press release (Exhibit 99.1) for detailed insights into ISRG's revenue, profitability, procedural volumes, and any forward-looking guidance provided for the quarter. This announcement is a key event for understanding the company's operational performance and financial health during the period.

Intuitive Surgical, Inc. (ISRG) filed an 8-K on May 2, 2022, reporting on outcomes from its Annual Meeting of Stockholders held on April 28, 2022. The primary focus of the filing is the stockholder approval of the amendment and restatement of the Amended and Restated 2010 Incentive Award Plan. This amendment increases the number of shares reserved for issuance under the plan and extends its term to 2032, indicating a continued commitment to equity-based compensation for employees and executives. Additionally, the filing provides details on the voting results for other key proposals presented at the Annual Meeting. All eleven director nominees were elected to serve a one-year term, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2022 was ratified. The compensation of Named Executive Officers was also approved on an advisory basis, signaling continued shareholder confidence in the company's leadership and governance practices.

Intuitive Surgical, Inc. (ISRG) reported its first quarter 2022 financial results, showcasing continued revenue growth driven by increased procedure volumes and system placements. Total revenue for the quarter rose 15% year-over-year to $1.49 billion, with significant contributions from instruments and accessories (+15%) and systems (+16%). The company saw a strong rebound in da Vinci procedures, up 19% year-over-year, indicating a recovery from COVID-19 related disruptions and solidifying the value proposition of minimally invasive care. The installed base of da Vinci systems also grew, reaching approximately 6,920 units, underscoring sustained market adoption. Despite the positive top-line growth, gross profit margin saw a slight decrease to 67.9% from 69.9% in the prior year, attributed to higher freight and material costs, lower system ASPs, and increased fixed costs. Operating income saw a modest decline of 2%, impacted by increased investments in R&D and SG&A expenses, which reflect ongoing strategic investments in innovation and operational capabilities. The company maintained a strong balance sheet with $8.40 billion in cash, cash equivalents, and investments as of March 31, 2022, though this balance decreased slightly from the prior quarter due to share repurchases and capital expenditures.

Intuitive Surgical, Inc. (ISRG) filed an 8-K on April 21, 2022, to announce its first-quarter financial results for the period ended March 31, 2022. The key takeaway from this filing is the release of their earnings press release, which provides investors with detailed performance metrics and financial condition updates for the quarter. While the 8-K itself does not contain the full financial statements, it directs readers to the furnished press release (Exhibit 99.1) for comprehensive information. Investors should review the press release for crucial data points such as revenue growth, procedure volumes, robot system placements, and profitability. The filing emphasizes that the information provided, including the press release, is furnished and not deemed 'filed' for liability purposes under Section 18 of the Exchange Act. This means the company is providing information to the public but not assuming the same level of legal responsibility as if it were part of a formal registration statement or periodic report.

Intuitive Surgical Inc. (ISRG) filed its 2021 10-K on February 3, 2022, reporting on its business operations and financial performance. The company, a leader in robotic-assisted minimally invasive surgery, saw a significant rebound in its business in 2021 following the disruptions of the COVID-19 pandemic in 2020. Total revenue grew 31% year-over-year, driven by strong performance across all segments, including systems, instruments, and accessories, and services. The company's core business continues to be driven by the adoption and utilization of its da Vinci Surgical Systems, which saw a 28% increase in procedures performed globally in 2021. This procedural growth fueled increased demand for instruments and accessories, as well as service revenue. Management highlighted strong system demand, with a 44% increase in da Vinci Surgical System placements compared to the prior year, indicating a recovery and expansion of its installed base. The company ended the year with a robust cash position and continues to invest in research and development to expand its product offerings and address new clinical applications.